Rheumatoid Arthritis, AnaptysBio

AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial
AnaptysBio’s trial saw 69% of its rheumatoid arthritis patients treated with rosnilimab achieve low disease activity by week 12.
AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in phase 2 trial
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has
AnaptysBio Shares Surge 37% After Mid-Stage Rheumatoid Arthritis Trial Meets Primary Goal
AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17. The stock is down about 44% over the last year.
Anaptys surges as arthritis therapy succeeds in mid-stage trial
Shares of AnaptysBio (NASDAQ:ANAB) climbed ~12% in the premarket on Wednesday after the biotech said its lead asset, rosnilimab, reached the main goals in a mid-stage trial targeted at the autoimmune disorder rheumatoid arthritis.
Rosnilimab shows promise in rheumatoid arthritis trial
SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for rosnilimab,
AnaptysBio price target raised to $22 from $19 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...
ENDPOINTS NEWS1h
Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis
AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year.
Yahoo Finance18h
AnaptysBio, Inc. (ANAB)
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor ...
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe ...
AnaptysBio stock soars on positive RA trial results
The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...
Analyst Expectations For AnaptysBio's Future
Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...
Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago
AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But ...
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint
AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...